| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5695263 | Gynecologic Oncology | 2017 | 5 Pages |
Abstract
In our racially diverse urban patients, 50% of patients received IV/IP chemotherapy and it was associated with improved overall survival compared to IV chemotherapy alone. Further investigation is needed to identify barriers to use of IV/IP chemotherapy.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Eirwen M. Miller, Joan Tymon-Rosario, Xianhong Xie, Xiaonan Xue, Gregory M. Gressel, Devin T. Miller, Dennis YS Kuo, Nicole S. Nevadunsky,